Diovan Positioned For Growth Following Sales Force Shift, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.